Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 20;59(5):1084–1093. doi: 10.1093/rheumatology/kez394

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Fig. 1 — Overall and progression-free survival in prospective investigation group patients

(A) Overall^a and (B) progression-free survival^b. ^aOne patient died 92 days after the end of 52-week tacrolimus treatment due to the exacerbation of interstitial pneumonitis that developed during the study period (on the 172nd day of the study), although it is not reflected in this figure. ^bKaplan–Meier estimates of time to death or ‘progression’ up to the end of the 52nd week in 25 prospective investigation group patients.